S&P 500

5.303,14

-0,34%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
NGM Biopharmaceuticals Inc (NGM)
NGM Biopharmaceuticals Inc (NGM) Notícias

NGM

NGM Biopharmaceuticals (NGM)

NGM Biopharmaceuticals Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:NGM

1 2 3 4 5 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
05/04/2024	10:19	GlobeNewswire Inc.	NGM Bio Announces Closing of Tender Offer	NASDAQ:NGM	NGM Biopharmaceuticals Inc
19/03/2024	18:30	GlobeNewswire Inc.	NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting	NASDAQ:NGM	NGM Biopharmaceuticals Inc
11/03/2024	17:15	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:NGM	NGM Biopharmaceuticals Inc
11/03/2024	17:13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NGM	NGM Biopharmaceuticals Inc
11/03/2024	17:05	GlobeNewswire Inc.	NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:NGM	NGM Biopharmaceuticals Inc
08/03/2024	19:32	Edgar (US Regulatory)	Form SC 13E3 - Going private transaction by certain issuers	NASDAQ:NGM	NGM Biopharmaceuticals Inc
08/03/2024	19:21	Edgar (US Regulatory)	Form SC 14D9 - Solicitation, recommendation statements	NASDAQ:NGM	NGM Biopharmaceuticals Inc
26/02/2024	19:11	Edgar (US Regulatory)	Form SC14D9C - Written communication relating to third party tender offer	NASDAQ:NGM	NGM Biopharmaceuticals Inc
26/02/2024	11:03	GlobeNewswire Inc.	NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP	NASDAQ:NGM	NGM Biopharmaceuticals Inc
20/02/2024	18:01	GlobeNewswire Inc.	NGM Bio to Participate in the Cowen 44th Annual Health Care Conference	NASDAQ:NGM	NGM Biopharmaceuticals Inc
14/02/2024	20:12	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:NGM	NGM Biopharmaceuticals Inc
18/01/2024	20:03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NGM	NGM Biopharmaceuticals Inc
17/01/2024	18:47	GlobeNewswire Inc.	NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference	NASDAQ:NGM	NGM Biopharmaceuticals Inc
09/01/2024	10:00	GlobeNewswire Inc.	NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need	NASDAQ:NGM	NGM Biopharmaceuticals Inc
13/11/2023	11:45	GlobeNewswire Inc.	NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®	NASDAQ:NGM	NGM Biopharmaceuticals Inc
08/11/2023	20:13	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:NGM	NGM Biopharmaceuticals Inc
07/11/2023	18:05	GlobeNewswire Inc.	NGM Bio to Participate in Upcoming Investor Conferences	NASDAQ:NGM	NGM Biopharmaceuticals Inc
02/11/2023	17:12	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:NGM	NGM Biopharmaceuticals Inc
02/11/2023	17:01	GlobeNewswire Inc.	NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights	NASDAQ:NGM	NGM Biopharmaceuticals Inc
11/10/2023	17:05	GlobeNewswire Inc.	NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®	NASDAQ:NGM	NGM Biopharmaceuticals Inc
27/09/2023	09:30	PR Newswire (US)	Alexandria Real Estate Equities, Inc.'s One-of-a-Kind, Essential Labspace Platform Empowers the Integration and Enhancement of Biological Discoveries Enabled by AI to Widen the Opportunities for and Accelerate the Development of Novel Medicines	NASDAQ:NGM	NGM Biopharmaceuticals Inc
11/09/2023	17:01	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:NGM	NGM Biopharmaceuticals Inc
07/08/2023	01:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:NGM	NGM Biopharmaceuticals Inc
04/08/2023	18:01	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:NGM	NGM Biopharmaceuticals Inc
04/08/2023	17:01	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NASDAQ:NGM	NGM Biopharmaceuticals Inc
03/08/2023	17:01	GlobeNewswire Inc.	NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights	NASDAQ:NGM	NGM Biopharmaceuticals Inc
08/06/2023	07:31	Edgar (US Regulatory)	Securities Registration Statement (simplified Form) (s-3)	NASDAQ:NGM	NGM Biopharmaceuticals Inc
08/06/2023	07:07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:NGM	NGM Biopharmaceuticals Inc
12/05/2023	18:55	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:NGM	NGM Biopharmaceuticals Inc
08/05/2023	17:05	GlobeNewswire Inc.	NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023	NASDAQ:NGM	NGM Biopharmaceuticals Inc